orphan receptor


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.
Related to orphan receptor: orphan drug, Protein kinase A, Nuclear receptor, orphan nuclear receptor

or·phan re·cep·tor

(ōr'făn rĕ-sep'tŏr)
A nuclear receptor for which no ligand has yet been identified.
Mentioned in ?
References in periodicals archive ?
By integrating these powerful platform technologies Axiom can rapidly identify novel organic small-molecule drug candidates for a wide variety of biological targets, including the products of newly discovered genes, well-defined molecular protein targets or orphan receptors.
These statements include, but are not limited to, statements regarding Omeros' expectation regarding its ability unlock orphan GPCRs and add a large number of new drug targets and their corresponding compounds to the market; the disorders that could potentially be treated by drugs that target unlocked orphan receptors, including GPR17, GPR153, CCRL2, LGR4, LGR6 and OPN5; Omeros' ability to obtain broad patent protection for the orphan GPCRs that it has unlocked; and the Company's ability to complete the screening of all Class A orphans by the end of 2012.
These statements include, but are not limited to, statements regarding Omeros' expectation regarding its ability unlock orphan GPCRs and add a large number of new drug targets and their corresponding compounds to the market; the disorders that could potentially be treated by drugs that target unlocked orphan receptors, including OGR1, GPR21, GPR50 and GPR52; Omeros' ability to obtain broad patent protection for the orphan GPCRs that it has unlocked; and the Company's ability to complete the screening of all Class A orphans by the end of 2012.
These statements include, but are not limited to, statements regarding Omeros' expectation regarding its ability unlock orphan GPCRs and add a large number of new drug targets and their corresponding compounds to the market; the disorders that could potentially be treated by drugs that target unlocked orphan receptors, including GPR25, GPR32, GPR80, GPR135 and MAS1; Omeros' ability to obtain broad patent protection for the orphan GPCRs that it has unlocked; the pharmaceutical industry's ability to design proprietary compounds that interact with these receptors; and the Company's ability to complete the screening of all Class A orphans by the end of 2012.
The four additional orphan receptors unlocked by Omeros are linked to important potential indications.
Both old and new targets are considered in terms of their potential to offer fresh opportunities, and particular attention is given to the current and future roles of orphan receptors.
The four unlocked orphan receptors announced today are linked to a wide range of indications and present multiple new opportunities for drug development by the pharmaceutical industry.
By identifying compounds that interact with these two orphan receptors, our proprietary screening technology has opened previously closed drug-development pathways for ALL and sleep disorders.